# Low-dose naltrexone (LDN) · PepVault guides

Source: https://pepvault.app/guides/low-dose-naltrexone

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [The science](https://pepvault.app/guides#science)

# Low-dose naltrexone (LDN): what it's used for and what the trials show

Reviewed November 2026 25 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

What low-dose naltrexone (LDN) is used for: every randomized trial by condition with its result against placebo, the long COVID trials and the opioid rule.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 25
- **Questions:** 7
- **Compounds:** 1

## The short answer

Low-dose naltrexone (LDN) is naltrexone, approved at 50 mg for alcohol and opioid dependence, prescribed off-label at about 1 to 6 mg a day for fibromyalgia, Crohn's disease, MS, long COVID and chronic pain. Its best result: 83% of Crohn's patients responded against 38% on placebo in one small trial. The three largest fibromyalgia trials found no benefit on pain. It blocks opioid painkillers; a prescriber decides if it fits.

Every number checked at its primary source · Nov 20, 2026 · [25 sources](https://pepvault.app/guides/low-dose-naltrexone#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomized human trials of 12 to 99 people per study, mostly small and mixed in result; no randomized long COVID trial has reported, and none has tested it alone for aging.

## What is low-dose naltrexone?

Naltrexone is an old, inexpensive drug that blocks opioid receptors. Its FDA-approved form is a 50 mg tablet for alcohol dependence and for blocking the effect of opioids in people recovering from opioid addiction[1](https://pepvault.app/guides/low-dose-naltrexone#source-1). Low-dose naltrexone, or LDN, is the same molecule at a tenth of that or less: the trials gave 1 to 6 mg a day, most often 4.5 mg.

No 4.5 mg product is approved, so LDN is used **off-label** (prescribed for a use the label does not cover) and is usually made up by a compounding pharmacy. One 2026 trial record says it plainly: LDN "is not a commercially available drug and will be compounded for this study"[20](https://pepvault.app/guides/low-dose-naltrexone#source-20).

The idea is different from the addiction use. A full dose blocks opioid receptors all day; a small dose once a day blocks them for a few hours. Naltrexone's half-life is about 4 hours, and its active breakdown product's about 13[1](https://pepvault.app/guides/low-dose-naltrexone#source-1). Researchers propose that the short block makes the body raise its own endorphins, and that naltrexone also calms microglia, the immune cells of the brain and spinal cord. Both are hypotheses; the label describes naltrexone as a pure opioid antagonist, a drug that only blocks[1](https://pepvault.app/guides/low-dose-naltrexone#source-1).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault logs a daily oral compound with a reminder at the time you set, so every dose sits in your history.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What is LDN used for, and what did the trials find?

Fibromyalgia, Crohn's disease, multiple sclerosis, long COVID, depression and chronic pain are the main uses. These are the randomized trials, condition by condition, each against placebo unless the row says otherwise. A crossover trial gives each person both LDN and placebo, one after the other.

| Condition | Trial | People, dose, length | Result |
| --- | --- | --- | --- |
| Fibromyalgia | Younger 2013, crossover[2](https://pepvault.app/guides/low-dose-naltrexone#source-2) | 31 women, 4.5 mg | Pain fell 28.8% on LDN vs 18.0% on placebo; responders 32% vs 11% |
| Fibromyalgia | Bested 2023, crossover[3](https://pepvault.app/guides/low-dose-naltrexone#source-3) | 58 people, 4.5 mg, about 3 weeks each | No clinically relevant difference in pain or function |
| Fibromyalgia | FINAL 2024[4](https://pepvault.app/guides/low-dose-naltrexone#source-4) | 99 women, 6 mg, 12 weeks | Pain down 1.3 points of 10 vs 0.9: not significant |
| Fibromyalgia | INNOVA 2026[5](https://pepvault.app/guides/low-dose-naltrexone#source-5) | 98 women, 4.5 mg, 12 months | Pain down 0.33 vs 0.64 at 3 months: no benefit |
| Crohn's disease | Smith 2011[7](https://pepvault.app/guides/low-dose-naltrexone#source-7) [8](https://pepvault.app/guides/low-dose-naltrexone#source-8) | 34 adults analysed, 4.5 mg, 12 weeks | Clinical response 83% vs 38%; less inflammation on colonoscopy 72% vs 25%; remission 30% vs 18%, not significant |
| Crohn's disease, children | Smith 2013[21](https://pepvault.app/guides/low-dose-naltrexone#source-21) | 14 children, up to 4.5 mg, 8 weeks | A safety trial: no serious side effects; 25% in remission after LDN, open-label weeks included |
| Crohn's disease | van de Pol 2026[9](https://pepvault.app/guides/low-dose-naltrexone#source-9) | 41 adults, 4.5 mg, 12 weeks | Stopped early for futility: healing on colonoscopy (the main measure) 6% vs 19%, clinical remission 22% vs 70% on placebo; fatigue improved |
| Multiple sclerosis | Cree 2010, crossover[10](https://pepvault.app/guides/low-dose-naltrexone#source-10) | 80 enrolled, 60 finished, 4.5 mg, 8 weeks | Mental-health quality of life up 3.3 points; pain-effects score better |
| Multiple sclerosis | Sharafaddinzadeh 2010[11](https://pepvault.app/guides/low-dose-naltrexone#source-11) | 96 adults, 17 weeks | No difference in quality of life |
| Depression, added to an antidepressant | Mischoulon 2017[12](https://pepvault.app/guides/low-dose-naltrexone#source-12) | 12 adults, 1 mg twice a day, 3 weeks | Main scale no different; a second depression scale favoured LDN |
| Depression, added to an antidepressant | Moloney 2026[13](https://pepvault.app/guides/low-dose-naltrexone#source-13) | 37 adults, up to 4.5 mg, 12 weeks | Depression score down 10.5 vs 9.8: no difference |
| Arthritis pain | VA pilot 2023, crossover[14](https://pepvault.app/guides/low-dose-naltrexone#source-14) | 23 finished, 4.5 mg, 8 weeks each | Pain interference down 23 vs 22: no difference |
| Diabetic nerve pain | Srinivasan 2021, against amitriptyline[15](https://pepvault.app/guides/low-dose-naltrexone#source-15) | 67 people, 2 to 4 mg, 6 weeks each | Pain relief matched amitriptyline, with 8 side-effect reports vs 52 |
| Long COVID | None reported[16](https://pepvault.app/guides/low-dose-naltrexone#source-16) | Searched to May 2026 | No randomized trial yet; four uncontrolled studies (155 people) reported less fatigue |

Each line is one trial. Look at fibromyalgia: the 2013 trial separates, the three larger ones since 2023 do not.

Read the pattern. In fibromyalgia the 2013 trial found a benefit[2](https://pepvault.app/guides/low-dose-naltrexone#source-2); the three trials since 2023, the largest so far, did not[3](https://pepvault.app/guides/low-dose-naltrexone#source-3) [4](https://pepvault.app/guides/low-dose-naltrexone#source-4) [5](https://pepvault.app/guides/low-dose-naltrexone#source-5). The pooled analyses split the same way: one pooling four trials found pain scores lower by 0.86 points[22](https://pepvault.app/guides/low-dose-naltrexone#source-22), one pooling seven chronic-pain trials found a small benefit in fibromyalgia only[23](https://pepvault.app/guides/low-dose-naltrexone#source-23), and one pooling eight found no difference from placebo[6](https://pepvault.app/guides/low-dose-naltrexone#source-6).

The strongest single win is Crohn's disease in 2011, where more than twice as many people responded on LDN as on placebo[7](https://pepvault.app/guides/low-dose-naltrexone#source-7) [8](https://pepvault.app/guides/low-dose-naltrexone#source-8). The 2026 Dutch trial did not repeat it[9](https://pepvault.app/guides/low-dose-naltrexone#source-9). The most practical result is in diabetic nerve pain: LDN relieved pain as well as amitriptyline, a standard drug for it, with far fewer side effects[15](https://pepvault.app/guides/low-dose-naltrexone#source-15).

## Does LDN work for long COVID?

Not known yet, and the answer is close. A 2026 review, searched to May 2026, found no randomized trial[16](https://pepvault.app/guides/low-dose-naltrexone#source-16). Four before-and-after studies of 155 people, on 1 to 6 mg a day, reported moderate drops in fatigue and brain fog and better sleep; without a placebo group, the size of any real effect is unknown[16](https://pepvault.app/guides/low-dose-naltrexone#source-16). These registered placebo trials report next, long COVID and ME/CFS first:

| Trial | Who | Size | State on Nov 20, 2026 |
| --- | --- | --- | --- |
| Post-COVID fatigue, British Columbia (NCT05430152)[17](https://pepvault.app/guides/low-dose-naltrexone#source-17) | Adults with fatigue after COVID | 160 | Finished February 2026; no results posted yet |
| Brave-LC, NIAID, phase 3 (NCT07916259)[18](https://pepvault.app/guides/low-dose-naltrexone#source-18) | Ages 6 to 25 with long COVID | 1,300 planned | Not yet recruiting; main results due end of 2028 |
| LIFT, Boston (NCT06366724)[19](https://pepvault.app/guides/low-dose-naltrexone#source-19) | ME/CFS and long COVID, with or without pyridostigmine | 160 planned | Recruiting; main results due September 2027 |
| ME/CFS dose-finding, Alabama (NCT07285473)[20](https://pepvault.app/guides/low-dose-naltrexone#source-20) | ME/CFS, 1.5 to 6 mg | 75 planned | Not yet recruiting; due April 2028 |
| Complex regional pain syndrome, Stanford (NCT02502162)[24](https://pepvault.app/guides/low-dose-naltrexone#source-24) | CRPS, a chronic limb-pain condition | 120 planned | Recruiting; due July 2027 |

The finished British Columbia trial is the next answer; LIFT is due in 2027 and Brave-LC at the end of 2028.

The British Columbia trial is the one to watch: it has finished, it is placebo-controlled, and its main measure is fatigue at 16 weeks[17](https://pepvault.app/guides/low-dose-naltrexone#source-17).

## With this guide

### Low-Dose Naltrexone

- [Low-Dose Naltrexone: the full reference](https://pepvault.app/peptides/low-dose-naltrexone)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Skin and longevity path

- [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)
- [Melanotan 1 vs 2: what each one does](https://pepvault.app/guides/melanotan-1-vs-melanotan-2)
- [What is Cerebrolysin? The trial evidence](https://pepvault.app/guides/cerebrolysin-explained)
- [Khavinson bioregulators, explained](https://pepvault.app/guides/khavinson-bioregulators-explained)
- [SS-31 (elamipretide): what the trials show](https://pepvault.app/guides/ss-31-elamipretide)
- [MOTS-c: the mouse and human studies](https://pepvault.app/guides/mots-c-studies)
- [SS-31 vs MOTS-c: where each works and what the human data show](https://pepvault.app/guides/ss-31-vs-mots-c)
- [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)
- [GHK-Cu vs minoxidil for hair: the evidence side by side](https://pepvault.app/guides/ghk-cu-vs-minoxidil-for-hair)
- [GHK-Cu injection vs topical: what the studies show](https://pepvault.app/guides/ghk-cu-injection-vs-topical)
- [Thymulin vs Thymalin: what's the difference?](https://pepvault.app/guides/thymulin-vs-thymalin)
- [Semax and Selank: what the studies found](https://pepvault.app/guides/semax-and-selank)
- [PT-141 (bremelanotide) for women and men: what the trials measured](https://pepvault.app/guides/pt-141-bremelanotide)
- [PT-141 nasal spray: does it work?](https://pepvault.app/guides/pt-141-nasal-spray)
- [How to reconstitute NAD+, and how often the studies gave it](https://pepvault.app/guides/nad-plus-mixing-and-how-often)
- [The FDA peptide panel explained: both meetings and what each vote means](https://pepvault.app/guides/fda-peptide-panel-explained)
- [Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?](https://pepvault.app/guides/ldn-and-pregnancy)
- [Do you stop low-dose naltrexone (LDN) before surgery or a colonoscopy?](https://pepvault.app/guides/ldn-before-surgery)
- [Does minoxidil cause hair loss?](https://pepvault.app/guides/minoxidil-shedding)
- [Can you take minoxidil with finasteride?](https://pepvault.app/guides/minoxidil-with-finasteride)
- [Peptides for hair growth: what the studies show](https://pepvault.app/guides/peptides-for-hair-growth)
- [Peptides for skin: what the human studies show](https://pepvault.app/guides/peptides-for-skin)
- [Do tanning peptides protect you from the sun?](https://pepvault.app/guides/tanning-peptides-and-the-sun)
- [Tretinoin vs retinol vs GHK-Cu for skin](https://pepvault.app/guides/tretinoin-vs-retinol-vs-ghk-cu)
- [Epitalon and telomeres: what was measured](https://pepvault.app/guides/epitalon-and-telomeres)
- [Dihexa: what is known, and what is not](https://pepvault.app/guides/dihexa-what-is-known)
- [Does Pinealon help sleep, and why does it make some people sleepy?](https://pepvault.app/guides/pinealon-and-sleep)
- [Selank vs oxytocin for anxiety: what the trials found](https://pepvault.app/guides/selank-vs-oxytocin-for-anxiety)
- [Oxytocin nasal spray: what it is used for](https://pepvault.app/guides/oxytocin-nasal-spray)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Crossover trial](https://pepvault.app/glossary/crossover-trial)

## What doses did the trials use?

These are the amounts researchers chose and monitored, set out to show what was studied, not a dose for any one person. Most trials gave 4.5 mg once a day[2](https://pepvault.app/guides/low-dose-naltrexone#source-2) [5](https://pepvault.app/guides/low-dose-naltrexone#source-5) [8](https://pepvault.app/guides/low-dose-naltrexone#source-8) [10](https://pepvault.app/guides/low-dose-naltrexone#source-10); FINAL used 6 mg[4](https://pepvault.app/guides/low-dose-naltrexone#source-4); the first depression trial 1 mg twice a day[12](https://pepvault.app/guides/low-dose-naltrexone#source-12). The newer trials start low and step up: the British Columbia trial went from 1 mg in week 1 to 4.5 mg by week 4[17](https://pepvault.app/guides/low-dose-naltrexone#source-17). For scale, the approved 50 mg blocks an injected opioid dose for up to 24 hours[1](https://pepvault.app/guides/low-dose-naltrexone#source-1).

<!--promo-->

PepVault logs a daily oral compound with a reminder at the time you set, so every dose sits in your history. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-low-dose-naltrexone-inline&mt=8)

<!--/promo-->

<!--promo-->

Its side-effect log records a symptom such as vivid dreams with a severity from 1 to 5 against the compound, a record to bring to your prescriber. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-low-dose-naltrexone-inline&mt=8)

<!--/promo-->

## What are the side effects of LDN?

In the two largest fibromyalgia trials, side effects were about as common on placebo. In FINAL, 84% on LDN reported one against 86% on placebo[4](https://pepvault.app/guides/low-dose-naltrexone#source-4); in INNOVA, 69% against 72%, mostly mild and short-lived[5](https://pepvault.app/guides/low-dose-naltrexone#source-5). Pooled across fibromyalgia trials, LDN brought more vivid dreams and nausea than placebo, and no more headache or dizziness[22](https://pepvault.app/guides/low-dose-naltrexone#source-22).

At the approved 50 mg, the label lists nausea (10%), headache (7%) and dizziness (4%) as the most common new complaints in its open-label safety study[1](https://pepvault.app/guides/low-dose-naltrexone#source-1).

**Commonly reported:** vivid dreams and lighter sleep in the first weeks, which tend to settle; some people say pain and fatigue ease gradually over the first couple of months.

## Can you take LDN with opioid painkillers?

No. The label rules naltrexone out for anyone taking opioid painkillers or dependent on opioids, including methadone and buprenorphine, because it blocks them and can bring on withdrawal[1](https://pepvault.app/guides/low-dose-naltrexone#source-1). The block can be overcome only with large amounts of opioid, which risks an overdose[1](https://pepvault.app/guides/low-dose-naltrexone#source-1). The label also warns of hepatitis and liver dysfunction seen with naltrexone, and exposure is about 5 to 10 times higher in cirrhosis[1](https://pepvault.app/guides/low-dose-naltrexone#source-1).

LDN is a prescription medicine used off-label, so your prescriber checks every medicine you take and plans around any procedure.

**When to get help** If you take LDN and need surgery, dental work or treatment for an injury, tell the clinician treating you first, because opioid pain relief will not work as expected[1](https://pepvault.app/guides/low-dose-naltrexone#source-1).

## So what is LDN good for?

LDN was well tolerated in the trials, is inexpensive and is widely used, and its record is mixed. It has not beaten placebo for fibromyalgia pain in the three largest trials[3](https://pepvault.app/guides/low-dose-naltrexone#source-3) [4](https://pepvault.app/guides/low-dose-naltrexone#source-4) [5](https://pepvault.app/guides/low-dose-naltrexone#source-5), its best Crohn's result was not repeated[8](https://pepvault.app/guides/low-dose-naltrexone#source-8) [9](https://pepvault.app/guides/low-dose-naltrexone#source-9), and it did not help depression when added to an antidepressant in the larger 2026 trial[13](https://pepvault.app/guides/low-dose-naltrexone#source-13). It matched a standard drug for diabetic nerve pain with fewer side effects[15](https://pepvault.app/guides/low-dose-naltrexone#source-15), and fatigue improved on it in the 2026 Crohn's trial[9](https://pepvault.app/guides/low-dose-naltrexone#source-9).

Long COVID is where the next answer comes from: a finished 160-person placebo trial and a 1,300-person NIH trial are on the way[17](https://pepvault.app/guides/low-dose-naltrexone#source-17) [18](https://pepvault.app/guides/low-dose-naltrexone#source-18). No trial has tested LDN alone for aging: the one healthspan pilot, 26 people, gave it together with rapamycin, metformin and NAD+, finished in April 2026 and has posted no results[25](https://pepvault.app/guides/low-dose-naltrexone#source-25).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Naltrexone hydrochloride tablets USP 50 mg, prescribing information (RemedyRepack). DailyMed, version of November 16, 2026: Indications and usage; Contraindications; Warnings; Clinical pharmacology; Adverse reactions. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f821dd49-3fa7-4d33-99de-19023ff1ae65)
2. Younger J et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013. [PubMed 23359310](https://pubmed.ncbi.nlm.nih.gov/23359310/)
3. Bested K et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023. [PubMed 38226027](https://pubmed.ncbi.nlm.nih.gov/38226027/)
4. Due Bruun K et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024. [PubMed 38258677](https://pubmed.ncbi.nlm.nih.gov/38258677/)
5. Rodríguez-Freire C et al. Efficacy of low-dose naltrexone in women with fibromyalgia syndrome: a 12-month randomised, double-blind, placebo-controlled single-centre clinical trial (INNOVA study). Eur J Pain. 2026. [PubMed 42385209](https://pubmed.ncbi.nlm.nih.gov/42385209/)
6. Ologunowa A et al. Efficacy of low-dose naltrexone in treating patients with fibromyalgia: systematic review and meta-analysis. J Pain Palliat Care Pharmacother. 2025. [PubMed 40272382](https://pubmed.ncbi.nlm.nih.gov/40272382/)
7. Parker CE et al. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018. [PubMed 29607497](https://pubmed.ncbi.nlm.nih.gov/29607497/)
8. Smith JP et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011. [PubMed 21380937](https://pubmed.ncbi.nlm.nih.gov/21380937/)
9. van de Pol N et al. Low-dose naltrexone in Crohn's disease: a prematurely terminated randomized trial showing reduced fatigue without clinical or endoscopic benefit. Dig Dis Sci. 2026. [PubMed 42701992](https://pubmed.ncbi.nlm.nih.gov/42701992/)
10. Cree BA et al. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010. [PubMed 20695007](https://pubmed.ncbi.nlm.nih.gov/20695007/)
11. Sharafaddinzadeh N et al. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010. [PubMed 20534644](https://pubmed.ncbi.nlm.nih.gov/20534644/)
12. Mischoulon D et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017. [PubMed 27736689](https://pubmed.ncbi.nlm.nih.gov/27736689/)
13. Moloney BD et al. Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study. Front Pharmacol. 2026. [PubMed 41868116](https://pubmed.ncbi.nlm.nih.gov/41868116/)
14. Beaudette-Zlatanova B et al. Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial. Clin Ther. 2023. [PubMed 37045708](https://pubmed.ncbi.nlm.nih.gov/37045708/)
15. Srinivasan A et al. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021. [PubMed 34014028](https://pubmed.ncbi.nlm.nih.gov/34014028/)
16. Byambasuren O et al. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026. [PubMed 42463201](https://pubmed.ncbi.nlm.nih.gov/42463201/)
17. ClinicalTrials.gov NCT05430152. A double-blind randomized trial of low-dose naltrexone for post-COVID fatigue syndrome (Women's Health Research Institute, Vancouver), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05430152)
18. ClinicalTrials.gov NCT07916259. Brave-LC: a phase 3 randomized, placebo-controlled trial of low-dose naltrexone for fatigue in people aged 6 through 25 with long COVID (NIAID), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916259)
19. ClinicalTrials.gov NCT06366724. LIFT: Life Improvement Trial, low-dose naltrexone and pyridostigmine in ME/CFS and long COVID (Brigham and Women's Hospital), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06366724)
20. ClinicalTrials.gov NCT07285473. Low-dose naltrexone for ME/CFS: dose-finding (University of Alabama at Birmingham), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285473)
21. Smith JP et al. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol. 2013. [PubMed 23188075](https://pubmed.ncbi.nlm.nih.gov/23188075/)
22. Vatvani AD et al. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain. 2024. [PubMed 39344363](https://pubmed.ncbi.nlm.nih.gov/39344363/)
23. Hegde NC et al. Low dose naltrexone in the management of chronic pain syndrome: a meta-analysis of randomized controlled clinical trials. Curr Pain Headache Rep. 2025. [PubMed 40540205](https://pubmed.ncbi.nlm.nih.gov/40540205/)
24. ClinicalTrials.gov NCT02502162. Low-dose naltrexone for the treatment of complex regional pain syndrome (Stanford University), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02502162)
25. ClinicalTrials.gov NCT07475546. A pilot randomized controlled study of combinatorial gerotherapeutics for healthspan improvement (AgelessRx), accessed November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475546)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · Skin and longevity

Guide · Skin and longevity

### [Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?](https://pepvault.app/guides/ldn-and-pregnancy)

LDN in pregnancy and before IVF: each naltrexone label's own pregnancy and breastfeeding lines, the human studies, the fertility trials and how fast it clears.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Low-Dose Naltrexone Studied range: 1–6 mg](https://pepvault.app/peptides/low-dose-naltrexone)

## Related guides

- Guide · Stacks

  ### [What to take alongside each peptide](https://pepvault.app/guides/what-to-take-with-peptides)

  What to pair with each peptide, and why: glycine and vitamin C for repair, less zinc on GHK-Cu, fasting and sleep for GH peptides, protein on GLP-1s.

  Read the guide
- Guide · Recovery

  ### [BPC-157: the human data we have](https://pepvault.app/guides/bpc-157-human-data)

  Every published human study of BPC-157: the knee pain, bladder pain and IV safety pilots, what each found, the trials now registered, and how it works.

  Read the guide
- Guide · Recovery

  ### [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)

  What GHK-Cu has shown in people for skin and hair: the serum and laser trials, the hair studies, what is lab-only, and what injecting it has never tested.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Low-Dose Naltrexone

- [Low-Dose Naltrexone: the full reference](https://pepvault.app/peptides/low-dose-naltrexone)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Skin and longevity path

- [GHK-Cu for skin and hair: what's measured](https://pepvault.app/guides/ghk-cu-skin-and-hair)
- [Melanotan 1 vs 2: what each one does](https://pepvault.app/guides/melanotan-1-vs-melanotan-2)
- [What is Cerebrolysin? The trial evidence](https://pepvault.app/guides/cerebrolysin-explained)
- [Khavinson bioregulators, explained](https://pepvault.app/guides/khavinson-bioregulators-explained)
- [SS-31 (elamipretide): what the trials show](https://pepvault.app/guides/ss-31-elamipretide)
- [MOTS-c: the mouse and human studies](https://pepvault.app/guides/mots-c-studies)
- [SS-31 vs MOTS-c: where each works and what the human data show](https://pepvault.app/guides/ss-31-vs-mots-c)
- [Are collagen peptides the same as research peptides?](https://pepvault.app/guides/collagen-vs-research-peptides)
- [GHK-Cu vs minoxidil for hair: the evidence side by side](https://pepvault.app/guides/ghk-cu-vs-minoxidil-for-hair)
- [GHK-Cu injection vs topical: what the studies show](https://pepvault.app/guides/ghk-cu-injection-vs-topical)
- [Thymulin vs Thymalin: what's the difference?](https://pepvault.app/guides/thymulin-vs-thymalin)
- [Semax and Selank: what the studies found](https://pepvault.app/guides/semax-and-selank)
- [PT-141 (bremelanotide) for women and men: what the trials measured](https://pepvault.app/guides/pt-141-bremelanotide)
- [PT-141 nasal spray: does it work?](https://pepvault.app/guides/pt-141-nasal-spray)
- [How to reconstitute NAD+, and how often the studies gave it](https://pepvault.app/guides/nad-plus-mixing-and-how-often)
- [The FDA peptide panel explained: both meetings and what each vote means](https://pepvault.app/guides/fda-peptide-panel-explained)
- [Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?](https://pepvault.app/guides/ldn-and-pregnancy)
- [Do you stop low-dose naltrexone (LDN) before surgery or a colonoscopy?](https://pepvault.app/guides/ldn-before-surgery)
- [Does minoxidil cause hair loss?](https://pepvault.app/guides/minoxidil-shedding)
- [Can you take minoxidil with finasteride?](https://pepvault.app/guides/minoxidil-with-finasteride)
- [Peptides for hair growth: what the studies show](https://pepvault.app/guides/peptides-for-hair-growth)
- [Peptides for skin: what the human studies show](https://pepvault.app/guides/peptides-for-skin)
- [Do tanning peptides protect you from the sun?](https://pepvault.app/guides/tanning-peptides-and-the-sun)
- [Tretinoin vs retinol vs GHK-Cu for skin](https://pepvault.app/guides/tretinoin-vs-retinol-vs-ghk-cu)
- [Epitalon and telomeres: what was measured](https://pepvault.app/guides/epitalon-and-telomeres)
- [Dihexa: what is known, and what is not](https://pepvault.app/guides/dihexa-what-is-known)
- [Does Pinealon help sleep, and why does it make some people sleepy?](https://pepvault.app/guides/pinealon-and-sleep)
- [Selank vs oxytocin for anxiety: what the trials found](https://pepvault.app/guides/selank-vs-oxytocin-for-anxiety)
- [Oxytocin nasal spray: what it is used for](https://pepvault.app/guides/oxytocin-nasal-spray)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Crossover trial](https://pepvault.app/glossary/crossover-trial)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
